# Antiva Biosciences, Inc.

> Antiva Biosciences is a clinical-stage biopharmaceutical company in South San Francisco developing topical, self-administered antiviral therapeutics for diseases caused by human papillomavirus (HPV). Its lead candidate, ABI-2280, is a vaginal tablet designed to clear high-risk HPV infection and treat pre-cancerous cervical lesions (CIN 2,3) without surgery - an approach aimed at preserving reproductive health and supporting the WHO's goal of eliminating cervical cancer.

- **Founded:** 2012
- **Headquarters:** South San Francisco, California, United States
- **Founders:** Karl Y. Hostetler (Scientific Founder (UC San Diego); pioneer of lipophilic prodrug chemistry)
- **Team size:** ~18 employees
- **Products:** ABI-2280, ABI-1968
- **Notable:** Posted positive Phase 1b/2 top-line results for ABI-2280: 46% HPV negativity at 12 weeks vs 16% placebo, with 87% durability at 24 weeks (139 patients)., Presented ABI-2280 data at the Society of Gynecologic Oncology (SGO) Annual Meeting 2026., Closed a $53M Series E in April 2023 led by MPM-BioImpact Capital.

## Products & services

- **ABI-2280** — Lead candidate: a topical, self-administered vaginal tablet formulated from a lipophilic antiviral prodrug. It blocks HPV DNA replication and induces apoptosis in infected cells, targeting both high-risk HPV infection and high-grade cervical intraepithelial neoplasia (CIN 2,3). In Phase 1b/2 with positive top-line data.
- **ABI-1968** — Earlier lead compound, a topical antiviral prodrug evaluated in Phase 1b studies for high-grade cervical (CIN 2,3) and anal dysplasia before the program advanced to ABI-2280.

## Achievements

- Posted positive Phase 1b/2 top-line results for ABI-2280: 46% HPV negativity at 12 weeks vs 16% placebo, with 87% durability at 24 weeks (139 patients).
- Presented ABI-2280 data at the Society of Gynecologic Oncology (SGO) Annual Meeting 2026.
- Closed a $53M Series E in April 2023 led by MPM-BioImpact Capital.
- Named a winner of a Global Women's Health innovation award (2022).
- Raised roughly $142M in total venture funding across Series C through E.

## Latest updates

- **2026-04** — Presented Phase 1b/2 data for ABI-2280 in cervical high-risk HPV infection at SGO 2026.
- **2025-09** — Announced positive top-line Phase 1b/2 results: 46% HPV negativity vs 16% placebo at week 12; 87% durability at week 24.
- **2023-04** — Closed $53M Series E and named Kristine Ball President & CEO; Gail Maderis became Board Chair.

## Links

- Website: https://antivabio.com
- LinkedIn: https://www.linkedin.com/company/antiva-biosciences-inc

---

Profile page: https://yespress.io/antiva-biosciences-inc
Published by YesPress — https://yespress.io
Last updated: 2026-07-13